AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...

AstraZeneca has reported a jump in quarterly sales thanks to record growth in its all-important US business, as the UK’s biggest drugmaker prepares to invest billions in the market ahead of potential ...

The UK’s largest listed companies are turning their heads towards the glimmer of the Nasdaq after growing impatient ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

The US, a critical market for the pharmaceutical industry, accounted for 44% of AstraZeneca’s total revenue in the second ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

SINGAPORE (Reuters) -Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major ...

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...